Removal of the bladder, called radical cystectomy, is the preferred treatment for patients with muscle-invasive bladder cancer (MIBC) as well as for some with non-muscle-invasive bladder cancer (NMIBC ...

Gross hematuria in a younger adult prompted rapid urologic evaluation, underscoring that bladder cancer can present before ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...